The stock of iBio Inc (IBIO) has seen a -6.31% decrease in the past week, with a 12.60% gain in the past month, and a -79.50% decrease in the past quarter. The volatility ratio for the week is 9.08%, and the volatility levels for the past 30 days are at 6.74% for IBIO. The simple moving average for the past 20 days is 2.96% for IBIO’s stock, with a -63.98% simple moving average for the past 200 days.
Is It Worth Investing in iBio Inc (NASDAQ: IBIO) Right Now?
IBIO has 36-month beta value of 0.94. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IBIO is 15.30M, and currently, short sellers hold a 4.14% ratio of that float. The average trading volume of IBIO on June 20, 2025 was 1.09M shares.
IBIO) stock’s latest price update
iBio Inc (NASDAQ: IBIO) has seen a rise in its stock price by 10.46 in relation to its previous close of 0.81. However, the company has experienced a -6.31% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-16 that iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23 rd SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the initiation of a NHP study for its Activin E engineered antibody candidate, now named IBIO-610. This preclinical study will evaluate the pharmacokinetics and early signs of efficacy of IBIO-610 in obese and elderly NHPs, including its impact on fat and body composition.
Analysts’ Opinion of IBIO
Many brokerage firms have already submitted their reports for IBIO stocks, with Chardan Capital Markets repeating the rating for IBIO by listing it as a “Buy.” The predicted price for IBIO in the upcoming period, according to Chardan Capital Markets is $5 based on the research report published on May 28, 2024 of the previous year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see IBIO reach a price target of $1.50. The rating they have provided for IBIO stocks is “Mkt Outperform” according to the report published on November 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to IBIO, setting the target price at $3 in the report published on January 22nd of the previous year.
IBIO Trading at -1.18% from the 50-Day Moving Average
After a stumble in the market that brought IBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.94% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IBIO starting from Duran Felipe, who purchase 9,191 shares at the price of $2.72 back on Jan 10 ’25. After this action, Duran Felipe now owns 11,139 shares of iBio Inc, valued at $25,000 using the latest closing price.
Brenner Martin, the of iBio Inc, purchase 9,191 shares at $2.72 during a trade that took place back on Jan 10 ’25, which means that Brenner Martin is holding 18,316 shares at $25,000 based on the most recent closing price.
Stock Fundamentals for IBIO
Current profitability levels for the company are sitting at:
- -44.83 for the present operating margin
- 2.98 for the gross margin
The net margin for iBio Inc stands at -55.98. The total capital return value is set at -1.23. Equity return is now at value -90.83, with -47.53 for asset returns.
Based on iBio Inc (IBIO), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -5.3. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is -73.74.
Currently, EBITDA for the company is -14.02 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 34.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.12.
Conclusion
To put it simply, iBio Inc (IBIO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
